|
[1]WANG FG,LIANG WF,XI JJ,et al.Establishment and applications of non-alcoholic steatohepatitis animal models[J].Chin J Clin Pharmacol Ther,2015,20(7):835-840.(in Chinese)王福根,梁伟峰,席建军,等.非酒精性脂肪性肝炎动物模型的建立与应用[J].中国临床药理学与治疗学,2015,20(7):835-840.
|
|
[2]LONARDO A,BALLESTRI S,MARCHESINI G,et al.Nonalcoholic fatty liver disease:a precursor of the metabolic syndrome[J].Dig Liver Dis,2015,47(3):181-190.
|
|
[3]DAY CP.Non-alcoholic steatohepatitis(NASH):where are we now and where are we going?[J].Gut,2002,50(5):85-88.
|
|
[4]VEENA J,MURAGUNDLA A,SIDGIDDI S,et al.Non-alcoholic fatty liver disease:need for a balanced nutritional source[J].Br J Nutr,2014,112(11):1858-1872.
|
|
[5]KAMADA N,SEO SU,CHEN GY,et al.Role of the gut microbiota in immunity and inflammatory disease[J].Nat Rev Immunol,2013,13(5):321-335.
|
|
[6]LIN HV,FRASSETTO A,KOWALIK EJ Jr,et al.Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms[J].PLo S One,2012,7(4):e35240.
|
|
[7]KALLIOMAKI M,COLLADO MC,SALMINEN S,et al.Early differences in fecal microbiota composition in children may predict overweight[J].Am J Clin Nutr,2008,87(3):534-538.
|
|
[8]BACKHED F,MANCHESTER JK,SEMENKOVICH CF,et al.Mechanisms underlying the resistance to diet-induced obesity in germ-free mice[J].Proc Natl Acad Sci U S A,2007,104(3):979-984.
|
|
[9]MA RJ,WU J,ZHOU YN,et al.Relationship between intestinal microflora imblance and nonalcoholic fatty liver disease[J].J Clin Hepatol,2015,31(1):127-129.(in Chinese)麻瑞娟,吴静,周永宁.肠道微生态失衡与非酒精性脂肪性肝病的关系[J].临床肝胆病杂志,2015,31(1):127-129.
|
|
[10]VIGGIANO D,IANIRO G,VANELLA G,et al.Gut barrier in health and disease:focus on childhood[J].Eur Rev Med Pharmacol Sci,2015,19(6):1077-1085.
|
|
[11]FEROLLA SM,ARMILIATO GN,COUTO CA,et al.Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease[J].World J Hepatol,2015,7(3):559-565.
|
|
[12]FUKUI H.Gut-liver axis in liver cirrhosis:how to manage leaky gut and endotoxemia[J].World J Hepatol,2015,7(3):425-442.
|
|
[13]ESPOSITO E,IACONO A,BIANCO G,et al.Probiotics reduce the inflammatory response indeced by a high-fat diet in the liver of young rats[J].J Nutr,2009,139(5):905-911.
|
|
[14]MENCARELLI A,CIPRIANI S,RENGA B,et al.VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation[J].PLo S One,2012,7(9):e45425.
|
|
[15]CHASSAING B,ETIENNE-MESMIN L,GEWIRTZ AT.Microbiota-liver axis in hepatic disease[J].Hepatology,2014,59(1):328-339.
|
|
[16]ROH YS,SEKI E.Toll-like receptors in alcoholic liver disease,non-alcoholic steatohepatitis and carcinogenesis[J].J Gastroenterol Hepatol,2013,28(Suppl 1):38-42.
|
|
[17]WOOD NJ.Dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression[J].Nat Rev Gastroenterol Hepatol,2012,9(3):123.
|
|
[18]HENAO-MEJIA J,ELINAV E,JIN C,et al.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J].Nature,2012,482(7384):179-185.
|
|
[19]FIALHO A,FIALHO A,THOTA P,et al.Small intestinal bacterial overgrowth is associated with nonalcoholic fatty liver disease[J].J Gastrointestin Liver Dis,2016,25(2):159-165.
|
|
[20]SHANAB AA,SCULLY P,CROSBIE O,et al.Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis:association with Toll-like receptor 4 expression and plasma levels of interleukin 8[J].Dig Dis Sci,2011,56(5):1524-3154.
|
|
[21]FEROLLA SM,ARMILIATO GN,COUTO CA,et al.The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease[J].Nutrients,2014,6(12):5583-5599.
|
|
[22]FUKUNISHI S,SUJISHI T,TAKESHITA A,et al.Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats[J].J Clin Biochem Nutr,2014,54:39-44.
|
|
[23]WELLS JM,ROSSI O,MEIJERINK M,et al.Epithelial cross-talk at the microbiota-mucosal interface[J].Proc Natl Acad Sci U S A,2011,108(Suppl 1):4607-4614.
|
|
[24] SHEN L,SU L,TURNER JR.Mechanisms and functional implications of intestinal barrier defects[J].Dig Dis,2009,27(4):443-449.
|
|
[25]MIELE L,VALENZA V,LA TORRE G,et al.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J].Hepatology,2009,49(6):1877-1887.
|
|
[26] ZHANG YY,LI J,CHI YJ,et al.Myosin light chain kinase involved in change of intestinal mucosal barrier function in nonalcoholic steatohepatitis mice model[J].Chin J Intern Med,2015,54(5):434-438.(in Chinese)张媛媛,李晶,迟毓静,等.肌球蛋白轻链激酶MLCK在非酒精性脂肪性肝炎小鼠模型肠粘膜屏障变化中的作用研究[J].中华内科杂志,2015,54(5):434-438.
|
|
[27]BIEGHS V,TRAUTWEIN C.Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease[J].Hepatobiliary Surg Nutr,2014,3(6):377-385.
|
|
[28]KIM CS,LEE SC,KIM YM,et al.Visceral fat accumulation induced by a high-fat diet causes the atrophy of mesenteric lymph nodes in obese mice[J].Obesity,2008,16(6):1261-1269.
|
|
[29]LU X,HAN T,TIAN Y,et al.Research progress in roles of gut microbiota and bile acid metabolism in development and progression of NAFLD[J].J Clin Hepatol,2014,30(11):1225-1228.(in Chinese)鲁旭,韩涛,田壵,等.肠道菌群面胆汁酸代谢对非酒精性脂肪性肝病发生发展的作用[J].临床肝胆病杂志,2014,30(11):1225-1228.
|
|
[30]MARTIN FP,DUMAS ME,WANG Y,et al.A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model[J].Mol Syst Biol,2007,3:112.
|
|
[31]MINEMURA M,SHIMIZU Y.Gut microbiota and liver diseases[J].World J Gastroenterol,2015,21(6):1691-1702.
|
DownLoad: